Severe Axonal Sensorimotor Peripheral Polyneuropathy in a 66-Year-Old Heavy Smoker
In a 66-year-old heavy smoker with severe axonal sensorimotor polyneuropathy, the most likely causes are diabetes mellitus (including pre-diabetes), vitamin B12 deficiency, monoclonal gammopathy, chronic obstructive pulmonary disease (COPD)-associated neuropathy, and vasculitic neuropathies such as EGPA, with smoking itself being a significant independent risk factor.
Diagnostic Approach
The evaluation should follow a systematic algorithm based on the highest-yield screening tests, as the comprehensive investigation combining history, examination, electrodiagnostic studies, and targeted laboratory testing yields an etiological diagnosis in 74-82% of polyneuropathy cases 1.
First-Tier Laboratory Testing (Highest Yield)
The three tests with the highest diagnostic yield must be performed first 1:
- Blood glucose testing - Diabetes is the most common cause of distal symmetric polyneuropathy, with approximately 11% of patients showing elevated blood glucose 1
- Glucose tolerance testing (GTT) should be strongly considered even if fasting glucose is normal, as 25-36% of patients with idiopathic axonal polyneuropathy have pre-diabetes (impaired glucose tolerance) 1
- Serum B12 with metabolites (methylmalonic acid ± homocysteine) - B12 deficiency occurs in 2.2-8% of polyneuropathy patients, with 44% having deficiency detected only by abnormal metabolites despite normal B12 levels 1
- Serum protein immunofixation electrophoresis (IFE) - Monoclonal gammopathy occurs in approximately 10% of polyneuropathy patients (versus lower rates in general population), with IFE detecting 30% more IgM gammopathies than standard SPEP 1
Second-Tier Testing
A comprehensive metabolic panel including:
- Complete blood count with differential (to assess for eosinophilia given smoking history and potential EGPA risk)
- Erythrocyte sedimentation rate
- Renal and liver function
- Thyroid function tests 1
Special Considerations for Heavy Smokers
Smoking is directly associated with polyneuropathy development 2. In COPD patients (common in heavy smokers), approximately 87% show electrophysiological abnormalities suggesting predominantly sensory axonal polyneuropathy, with clinical signs in 27% 2. The presence of polyneuropathy correlates with age, disease duration, and smoking intensity 2.
Critical Red Flags Requiring Expanded Workup
If the patient has asthma history or respiratory symptoms, strongly consider EGPA (eosinophilic granulomatosis with polyangiitis), which can present as severe axonal sensorimotor polyneuropathy with marked hypereosinophilia and positive ANCA 3. This requires:
- Eosinophil count
- ANCA testing
- Chest imaging if respiratory symptoms present
Etiological Distribution in Axonal Patterns
Axonal sensorimotor polyneuropathies show greater etiological heterogeneity than demyelinating patterns 4. In a large tertiary center study, the main causes were:
- Inflammatory (23.7%)
- Hereditary (18.9%)
- Idiopathic (13.7%)
- Multifactorial (11.1%)
- Diabetes (10.8%) 4
However, idiopathic and multifactorial etiologies predominate specifically in axonal patterns 4, making the comprehensive screening even more critical to exclude treatable causes.
Common Pitfalls
Do not rely on serum B12 alone - methylmalonic acid is 98.4% sensitive and more specific than homocysteine (which can be elevated in folate deficiency, pyridoxine deficiency, hypothyroidism, and renal insufficiency) 1.
Do not assume normal fasting glucose excludes metabolic causes - glucose tolerance testing identifies an additional 25-36% of patients with pre-diabetes who have normal fasting glucose 1.
Do not use standard SPEP instead of immunofixation - IFE detects 30% more small monoclonal proteins, particularly IgM gammopathies <5g/L 1.
Age and Smoking Context
At age 66, the differential broadens to include age-related factors, but the heavy smoking history specifically increases risk for:
- COPD-associated axonal polyneuropathy 2
- Vasculitic neuropathies (if concurrent autoimmune disease)
- Accelerated metabolic dysfunction
- Multifactorial polyneuropathy with combined risk factors 4, 5
The severity of the presentation (described as "severe") suggests either a rapidly progressive inflammatory/vasculitic process, severe metabolic derangement, or toxic exposure that warrants urgent systematic evaluation following the algorithm above 5, 6.